In patients with PTC, a lower level of GAS5 expression is linked with poor prognosis, tumour nodules metastasis (TNM) staging, multiple cancer foci, and lymph node metastasis (63). Here, GAS5 is linked to metastatic malignant neoplasm in the lymph nodes.